Clinical trials: Anti-coagulation Therapy
Atrial Fibrillation, Deep Vein Thrombosis
Predictors of Anticoagulation Control on Warfarin Therapy
The goal of this research study is to develop better dosing of anticoagulation medication in both Caucasian and African Americans through analysis of various genetic factors.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Heart Valve Replacement
- Trial name
- NCT00905177
- Where
- 2 sites in United States
- Volunteers
- 687 people
- Sponsor
- University of Pennsylvania
Acute Thrombosis of Deep Veins of Proximal Lower Extremity
DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT.
Rationale: Iliofemoral deep venous thrombosis (IFDVT) is associated with significant post thrombotic morbidity. The presence of both obstruction and reflux significantly increases the chances for development of post-thrombotic…
- Trial name
- NL28394 (NCT00970619)
- Testing
- Ekos endowave system thrombolysis
- Where
- 16 sites in Netherlands
- Volunteers
- 184 people
- Sponsor
- Maastricht University Medical Center
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of primary immune thrombocytopenia in patients who have failed first-line treatment.
- Trial name
- NCT06838962
- Testing
- Daratumumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Kidney Injury, Acute Kidney Failure
HEmoFiltration With Citric Acid Anticoagulation
Prospective observational study of all consecutive cardio-vascular surgical patients treated with post-dilution hemofiltration with regional citrate anticoagulation as first-choice anticoagulation method.
- Conditions
- Acute Kidney Injury, Acute Kidney Failure, Renal Replacement Therapy, Hemofiltration
- Trial name
- HEFCAA (NCT03836742)
- Testing
- Hemofiltration with regional citrate anticoagulation
- Where
- Poland
- Volunteers
- 54 people
- Sponsor
- Medical University of Gdansk
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Atrial Fibrillation
Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy
Study objective is to demonstrate that anticoagulation with the direct factor Xa inhibitor apixaban is not less safe than Vitamin-K-antagonists (VKA) therapy in patients undergoing catheter ablation of non-valvular AF in the…
- Trial name
- AXAFA (NCT02227550)
- Testing
- Vitamin K antagonist, Apixaban
- Where
- 13 sites in United States, Austria and 7 more
- Volunteers
- 676 people
- Sponsor
- Atrial Fibrillation Network
GERD
Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)
Background and Rationale: Gastroesophageal reflux disease is affecting 1 in 3 US adults with half experiencing daily symptoms. Per recent data, more than 50% continue to experience daily symptoms despite taking medical therapy…
- Trial name
- AREA (NCT06641375)
- Testing
- Anti reflux endoscopic theraphy, Endoscopy
- Where
- India
- Volunteers
- 18 people
- Sponsor
- Asian Institute of Gastroenterology, India
Valve Heart Disease, Anticoagulants; Increased
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months oral anticoagulation therapy after operation.
- Trial name
- REDUCE (NCT03885180)
- Testing
- Warfarin Sodium
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Wuhan Asia Heart Hospital
Bleeding, Ischemic Stroke
The Relationship Between Clotting Factor VIII and Bleeding Adverse Reactions in Patients Under the Therapies of Thrombolysis, Anticoagulation and Anti-platelet
The purpose of this study is to determine whether Plasma Factor VIII Levels are related to the treatment of bleeding in ischemic stroke（IS）.
- Trial name
- NCT02677818
- Where
- China
- Sponsor
- Zhujiang Hospital
Anti-coagulation Therapy, DVT
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
The WARFARIN Study is a clinical trial designed to determine if the use of genetic information related to warfarin sensitivity can help create a dose of warfarin that will result in less hospitalizations and deaths related to…
- Conditions
- Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple
- Trial name
- WARFARIN (NCT01305148)
- Testing
- Warfarin GenoSTAT Test
- Where
- 56 sites in United States
- Volunteers
- 3,800 people
- Sponsor
- Iverson Genetic Diagnostics, Inc.
Atrial Fibrillation, Deep Vein Thrombosis
Genotype-Guided Warfarin Therapy Trial
The purpose of the investigators' study is to determine the clinical utility of a warfarin-dosing algorithm that incorporates genetic information (VKORC1 and CYP2C9 alleles) for adult patients initiating warfarin therapy.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Artificial Heart Valve
- Trial name
- WARFPGX (NCT00904293)
- Testing
- Genotype-guided dose determination, Non-genotype guided warfarin dosing
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of North Carolina, Chapel Hill
Stroke
PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
The purpose of the study is to determine the effectiveness and safety of LMWH postoperative bridging therapy (standard of care) versus postoperative placebo bridging therapy (experimental arm)for patients with mechanical heart…
- Trial name
- NCT00432796
- Testing
- Dalteparin
- Where
- 8 sites in Canada, India
- Volunteers
- 1,473 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pulmonary Embolism
Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism
The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE) at intermediate risk, it is effective to…
- Trial name
- MONALYSE (NCT02604238)
- Testing
- Alteplase
- Sponsor
- Azienda U.S.L. 1 di Massa e Carrara
Venous Thrombosis, Neoplasms
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
The purpose of this study is to determine the optimal duration of anticoagulation therapy (3 months versus 12 months) with direct oral anticoagulant (edoxaban) for isolated distal deep vein thrombosis.
- Conditions
- Venous Thrombosis, Neoplasms, Anticoagulant
- Trial name
- ONCO DVT (NCT03895502)
- Testing
- 12-month Edoxaban, 3-month Edoxaban
- Where
- Japan
- Volunteers
- 605 people
- Sponsor
- Takeshi Morimoto
Renal Injury, Regional Citrate Anticoagulation
Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions
It is unclear whether different modes of continuous renal replacement therapy (CRRT) impact post-filter ionized calcium concentrations during regional citrate anticoagulation (RCA) when using calcium-containing replacement fluid.
- Conditions
- Renal Injury, Regional Citrate Anticoagulation, Continuous Renal Replacement Therapy
- Trial name
- NCT06021080
- Testing
- CVVH, CVVHD
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Provincial Hospital
Pulmonary Embolism
PEITHO Pulmonary Embolism Thrombolysis Study
Heparin is the reference therapy for most patients with pulmonary embolism. Some patients with sub-massive pulmonary embolism defined by normal blood pressure and dysfunction of the right ventricle have a higher mortality risk.
- Trial name
- PEITHO (NCT00639743)
- Testing
- tenecteplase (group A)
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 1,005 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adults Undergoing Oral Anticoagulation Therapy
Developing Anticoagulation Self-Report Measure in Adults
The use of oral anticoagulants has been increasing globally to prevent strokes associated with atrial fibrillation and heart valve replacements.
- Trial name
- PERSONAE (NCT05973240)
- Testing
- Participation in an web-based survey
- Where
- Italy
- Sponsor
- IRCCS Policlinico S. Donato
Idiopathic Thrombocytopenic Purpura
Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D
The purpose of this study is to describe the effect of anti-D on symptoms and platelet count in children suffering from unexplainable low platelet counts, when anti-D is administered as an injection under the skin.
- Trial name
- NCT00128882
- Testing
- Anti-D
- Where
- 17 sites in Denmark
- Volunteers
- 45 people
- Sponsor
- University of Aarhus
Critical Illness, Multi Organ Failure
Parathyroid Hormone Kinetics During CRRT
The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation…
- Conditions
- Critical Illness, Multi Organ Failure, Renal Failure, Circulatory Failure
- Trial name
- NCT03873675
- Testing
- parathyroid hormone
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Uniwersytecki Szpital Kliniczny w Opolu
Aortic Stenosis
AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation
ACASA-TAVI is a pragmatic randomized controlled trial assessing the value of anticoagulation therapy versus the standard antiplatelet therapy after transcatheter aortic valve implantation in patients with aortic stenosis.
- Trial name
- ACASA-TAVI (NCT05035277)
- Testing
- Acetylsalicylic acid, Apixaban, Rivaroxaban
- Where
- 3 sites in Norway
- Volunteers
- 360 people
- Sponsor
- Oslo University Hospital